Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment
Mandate

Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment

July 12, 2019 Capital Markets and Public M&A

The Norwegian energy company Equinor ASA announced on 7 July that it had agreed with Lundin Petroleum AB (publ) to divest around 54.5 million shares in Lundin Petroleum for a total consideration of around USD 1.56 billion and to acquire 2.6% of the development project Johan Sverdrup for a cash consideration of USD 910 million.  

Equinor ASA is a global energy company with more than 20,000 employees and business in more than 30 countries. Equinor is the largest oil and gas operator in Norway, one of the largest offshore operators globally and has a growing portfolio of renewable assets in wind and solar power.
 
Vinge’s team consisted of Dain Hård Nevonen, David Andersson, Johan Karlsson och Anna Grigorian.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

 Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026